company background image
AEZS logo

Aeterna Zentaris TSX:AEZS Stock Report

Last Price

CA$2.65

Market Cap

CA$12.9m

7D

9.5%

1Y

-40.2%

Updated

27 Feb, 2024

Data

Company Financials +

AEZS Stock Overview

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests.

AEZS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Aeterna Zentaris Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aeterna Zentaris
Historical stock prices
Current Share PriceCA$2.65
52 Week HighCA$4.59
52 Week LowCA$1.91
Beta2.02
1 Month Change3.92%
3 Month Change-2.21%
1 Year Change-40.18%
3 Year Change-92.54%
5 Year Change-97.95%
Change since IPO-100.00%

Recent News & Updates

Recent updates

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

May 10
We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Nov 12
We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Jul 15
Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Mar 29
Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Feb 04
Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Shareholder Returns

AEZSCA BiotechsCA Market
7D9.5%-0.05%0.6%
1Y-40.2%-22.4%3.0%

Return vs Industry: AEZS underperformed the Canadian Biotechs industry which returned -23.3% over the past year.

Return vs Market: AEZS underperformed the Canadian Market which returned 3.6% over the past year.

Price Volatility

Is AEZS's price volatile compared to industry and market?
AEZS volatility
AEZS Average Weekly Movement9.1%
Biotechs Industry Average Movement12.3%
Market Average Movement8.6%
10% most volatile stocks in CA Market17.6%
10% least volatile stocks in CA Market3.2%

Stable Share Price: AEZS has not had significant price volatility in the past 3 months.

Volatility Over Time: AEZS's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990n/aKlaus Paulinihttps://www.zentaris.com

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.

Aeterna Zentaris Inc. Fundamentals Summary

How do Aeterna Zentaris's earnings and revenue compare to its market cap?
AEZS fundamental statistics
Market capCA$12.87m
Earnings (TTM)-CA$31.56m
Revenue (TTM)CA$9.27m

1.4x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AEZS income statement (TTM)
RevenueUS$6.86m
Cost of RevenueUS$218.00k
Gross ProfitUS$6.64m
Other ExpensesUS$30.01m
Earnings-US$23.37m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.81
Gross Margin96.82%
Net Profit Margin-340.54%
Debt/Equity Ratio0%

How did AEZS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.